Carthera®

“Advanced Brain Therapies Through Innovation” 

CarThera® designs and develops innovative medical devices using the therapeutic potential of ultrasound to significantly improve the efficacy, comfort, and cost of treating a range of medical conditions.

CarThera® has focused on the treatment of brain tumors for the first applications of its innovative medical devices. CarThera’s devices are developed by a multidisciplinary team of medical doctors, biologists, and physicists. This multidisciplinary effort takes into account, from the early stages of development, the needs of both patients and physicians, and leads to innovative solutions.

The medical devices developed by CarThera originate from the work of Dr. Alexandre Carpentier, a neurosurgeon at the University Hospital Pitié-Salpêtrière in Paris, France. They are designed to respond to unmet clinical needs.

 

The two medical devices currently in development are designed to be used during outpatient procedures for the thermal ablation of brain tumors (SonoProbe) and for improving the efficacy of chemotherapy (SonoCloud®).

Both devices are innovative at multiple levels: 

Biologically — They employ the use of new tissue-ultrasound interactions. 

Clinically — They use interventional MRI procedures for the brain. 

Technologically — They use advanced technology for miniaturization. 

Organizationally — They open the possibility of new methods of outpatient care.

 

 

photo_carpentier

Pr Carpentier Interview  / Autrement Editions – may 2011.

 

 

 

« A new vision of surgery »

“I have always been interested in the development of new surgical technologies. Even though current surgical techniques provide an immense benefit to patients, I’m convinced that we can do even better, with the development of techniques that decrease both invasiveness and expense.  My medical objective is a bit idealistic: I envision surgery as a convergence of medical expertise, advanced materials, physical principles, and computational power. Such a convergence will allow for treatments with better efficacy and security, with diminished morbidity, under local anaesthesia, and on an outpatient basis. It may appear unfeasible, but we are on the way to success: We now have proof of concept and efficacy in pre-clinical studies for our two technologies under development.”

 

  • unnamed-2
    unnamed-3

     
  • News CarThera

    06.01.2021
    December 2020: CarThera starts phase I/II trial in collaboration with Northwestern University

    CarThera announces the launch of a new phase I/II clinical trial (NCT04528680) in collaboration with Northwestern University in Chicago. The trial will recruit up to 39 patients with recurrent glioblastoma (GBM) to test the SonoCloud-9 device in combination with Abraxane® – an albumin-bound formulation of paclitaxel. The first patient in this trial has been treated and further patient recruitment is now on-going. The goal of the trial is to determine the safe dose of Abraxane to be used in combination with the SonoCloud-9 device in recurrent GBM patients (Phase I); then expand with the established safe dose in order to evaluate preliminary efficacy (Phase II).

    06.01.2021
    September 2020: CarThera to receive €2M grant and €10.5M equity from the European Innovation Council

    CarThera announces that it has been selected by the EIC Accelerator Pilot to receive a €2 million ($2.3M) grant and €10.5M ($12M) in equity for the development of its DOMEUS project for the treatment of glioblastoma (GBM) patients. The company will also receive business coaching and mentoring to accompany its growth. With the DOMEUS project, CarThera will be able to scale-up its processes and organizational structure to bring its technology to an increasing number of patients around the world.

    09.06.2020
    June 2020: CarThera announces enrollment of first melanoma patient in new clinical trial for SonoCloud technology

    CarThera announces that the first patient has been enrolled and treated in a clinical trial evaluating the safety of using its SonoCloud® technology in combination with checkpoint inhibitors for the treatment of brain metastases from melanoma (NCT04021420). In this trial, anti-PD1 alone or in combination with anti-CTLA4 are administered in patients before SonoCloud-mediated Blood Brain Barrier opening (BBB). BBB opening can help boost the brain’s immunity and increase brain penetration of newly approved systemically delivered immunotherapies, such as checkpoint inhibitors. This could translate into controlling brain disease with the same magnitude as peripheral diseases, improving clinical outcomes for many patients worldwide.